Actively Recruiting
Immune Profiling for Cancer Immunotherapy Response
Led by Dartmouth-Hitchcock Medical Center · Updated on 2025-12-16
1500
Participants Needed
1
Research Sites
104 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are evaluating immune-methylation profiling and cytokine profiling to predict how patients with various types of cancer respond to FDA-approved immunotherapy treatments. This observational study includes patients undergoing standard immunotherapy, hematologic malignancy transplants, or CAR T cell therapy. The goal is to better understand immune responses across and within cancer types to guide future treatments. Participants will be observed while receiving their usual FDA-approved immunotherapy or undergoing transplant or CAR T therapy. Methylation cytometry tests will be performed on blood samples before treatment and repeatedly during therapy to assess immune markers. There is no experimental drug or intervention; the study focuses on diagnostic testing alongside standard care. During the study, participants will have blood samples taken at multiple times to monitor immune-methylation and cytokine profiles. Researchers will track responses to therapy over five years to evaluate how well these immune profiles predict treatment outcomes. Participants will continue their usual medical care while contributing data through blood tests and clinical monitoring throughout the study period.
CONDITIONS
Brief Title
Immune Profiling for Cancer Immunotherapy Response
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Cancer patients receiving or will receive immunotherapy under FDA-approved indication (e.g. checkpoint inhibitor therapy with pembrolizumab, nivolumab, or ipilimumab, or cellular immunotherapy).
- Participants are eligible regardless of the type of prior therapy (i.e. prior immunotherapy treated participants can be included).
- Adults aged 18 years or older
You will not qualify if you...
- Pregnant women, fetuses, or neonates
- Prisoners
- Individuals unable to make decisions about their medical care
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Duration of treatment period
Participants undergo Methylation Cytometry assessments on peripheral blood before and during treatment to evaluate immune response and predict treatment outcomes or adverse events.
Repeated blood sample collections during treatment
Duration - Up to 5 years
Participants are observed for up to 5 years to assess response to immunotherapy and long-term outcomes.
Follow-up visits depending on treatment arm and clinical care
Trial Site Locations
Total: 1 location
1
Dartmouth-Hitchcock Medical Center
Lebanon, New Hampshire, United States, 03756
Actively Recruiting
Research Team
B
Brock C Christensen, PhD
H
Hannah G Stolrow, BA
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
3
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here